VIP-236 is under clinical development by Vincerx Pharma and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VIP-236’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VIP-236 overview
VIP-236 is under development for the treatment of advanced and metastatic solid tumors like small cell lung cancer (SCLC), non-small cell lung cancer, adeno cystic carcinoma, renal cell carcinoma(RCC), ovarian cancer, colorectal cancer (CRC), triple negative breast cancer(TNBC) and ovarian cancer, biliary tract cancers, cervical cancer, gastric cancer/gastroesophageal junction adenocarcinoma, fallopian tube cancer, primary peritoneal cancer, pancreatic adenocarcinoma, small cell lung cancer, urothelial cancer, breast cancer, sarcomas, endometrial cancer. It is administered by intravenous route. The drug candidate is a small molecule drug conjugate (SMDC) consisting of an alpha v beta 3 integrin binder and a linker that is cleavable by neutrophil elastase. The payload is a modified camptothecin derivative designed for extracellular release. It is being developed based on VersAptx Platform.
Vincerx Pharma overview
Vincerx Pharma (Vincera) is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of oncology therapeutics. The company’s products include ENITOCICLIB, a CDK9 inhibitor, and several antibody-drug conjugates (ADCs) such as VIP236, VIP943, VIP924, and others targeting solid tumors. Vincera’s products are also used for the treatment of various types of cancers including diffuse large B-cell lymphoma (DLBCL), non-GCB DLBCL, peripheral T-cell lymphoma, leukemias, myelodysplastic syndrome (MDS), and multiple solid tumors. The company operates in the US. Vincera is headquartered in Santa Clara, California, the US.
For a complete picture of VIP-236’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
